SARS-CoV-2

Showing 1 - 25 of 246

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Recruiting
  • SARS-CoV-2
  • SPIKEVAX
  • New York, New York
    Aetion, Inc
Nov 8, 2023

Booster Dose of Comirnaty in Children Ages 6 Months Though 4

Not yet recruiting
  • SARS-CoV-2
  • COVID-19
  • COMIRNATY intramuscular injection
  • Tokyo, Japan
    Pfizer Local Country
Nov 8, 2023

SARS-CoV-2, Prevention Trial in Chongqing (A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray, A8G6 SARS-CoV-2

Recruiting
  • SARS-CoV-2
  • Prevention
  • A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray
  • A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient
  • Chongqing, Chongqing, China
    The Second Affiliated Hospital of Chongqing Medical University
Nov 9, 2023

SARS-CoV-2, Influenza Trial in Canada, United States (mRNA-1083, Placebo, Influenza Vaccine)

Not yet recruiting
  • SARS-CoV-2
  • Influenza
  • mRNA-1083
  • +3 more
  • Anniston, Alabama
  • +172 more
Oct 18, 2023

COVID-19, SARS-CoV-2 Trial in United States (VYD222, Normal saline)

Recruiting
  • COVID-19
  • SARS-CoV-2
  • Culver City, California
  • +15 more
Sep 8, 2023

COVID-19, SARS-CoV-2 Trial in Spain (Ivermectin, Placebo)

Terminated
  • COVID-19
  • SARS-CoV-2
  • El Ejido, Almeria, Spain
  • +19 more
Aug 10, 2023

SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586

Recruiting
  • SARS-CoV-2
  • Prevention
  • MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
  • Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
  • Chongqing, Chongqing, China
    The Second Affiliated Hospital of Chongqing Medical University
Aug 2, 2023

SARS-CoV-2 Trial (CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose)

Not yet recruiting
  • SARS-CoV-2
  • CV0701 Bivalent High dose
  • +4 more
  • (no location specified)
Jul 24, 2023

SARS-CoV-2 Trial in Worldwide (Upamostat, Placebo (PO))

Not yet recruiting
  • SARS-CoV-2
  • Baltimore, Maryland
  • +5 more
Jul 19, 2023

COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2 Trial (Tafenoquine Oral Tablet, Placebo)

Not yet recruiting
  • COVID 19 Disease
  • +4 more
  • Tafenoquine Oral Tablet
  • Placebo
  • (no location specified)
Jul 13, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • Saline
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

SARS-CoV, SARS-CoV-2 Trial in Durban, Soweto (VXCO-100, COVID-19 mRNA vaccine and VXCO-100, COVID-19 mRNA vaccine)

Not yet recruiting
  • SARS-CoV
  • SARS-CoV-2
  • VXCO-100
  • +2 more
  • Durban, South Africa
  • +1 more
Jul 5, 2023

A Study of the Effectiveness of Moderna COVID-19 Vaccine

Recruiting
  • SARS-CoV-2
  • COVID-19
  • mRNA-1273
  • Pasadena, California
    Kaiser Permanente Southern California
Jul 5, 2023

SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)

Active, not recruiting
  • SARS-CoV-2
  • RBMRNA-176
  • Placebo
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 mRNA vaccine (RBMRNA)
  • CoronaVac®
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

Japan of Shock and Anaphylaxis After Severe Acute Respiratory

Active, not recruiting
  • SARS-CoV-2
    • Tokyo, Japan
      CMIC Co., Ltd.
    Jun 5, 2023

    Japan After Severe Acute Respiratory Syndrome Coronavirus 2

    Not yet recruiting
    • SARS-CoV-2
      • Tokyo, Japan
        CMIC Co., Ltd
      Jun 6, 2023

      Severe Exacerbation of Severe Acute Respiratory Syndrome

      Active, not recruiting
      • SARS-CoV-2
        • Tokyo, Japan
          CMIC Co. Ltd.,
        Jun 5, 2023

        Optical Quality During the Peak of the Covid-19 Pandemic

        Completed
        • Corneal Wavefront Aberration
        • SARS-CoV-2
          • Tianjin, Tianjin, China
            Tianjin Eye Hospital
          May 27, 2023

          COVID-19 Vaccines Using Information From California State

          Not yet recruiting
          • SARS-CoV-2
          • +2 more
          • Pfizer-BioNTech COVID-19 bivalent mRNA vaccine
          • (no location specified)
          May 23, 2023

          COVID-19, SARS-CoV-2 Trial in Seoul (QTP104 1ug, QTP104 5ug, QTP104 25ug)

          Active, not recruiting
          • COVID-19
          • SARS-CoV-2
          • QTP104 1ug
          • +2 more
          • Seoul, Korea, Republic of
          • +1 more
          May 24, 2023

          SARS-CoV, SARS-CoV-2 Trial in Decatur, Baltimore, Rochester (VXCO-100)

          Recruiting
          • SARS-CoV
          • SARS-CoV-2
          • VXCO-100
          • Decatur, Georgia
          • +2 more
          May 19, 2023

          SARS-CoV-2, Influenza Trial in United States (Fluarix, mRNA-1083.1, mRNA-1083.2)

          Recruiting
          • SARS-CoV-2
          • Influenza
          • Fluarix
          • +8 more
          • Chandler, Arizona
          • +68 more
          Apr 24, 2023

          SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)

          Recruiting
          • SARS-CoV-2
          • SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
          • 0.9% sodium chloride solution
          • Islamabad, Pakistan
            Sindh Infectious Diseases Hospital & Research Center Dow Univers
          Apr 16, 2023